Skip to main content
ADCES 2026 Annual Conference Main banner

Cardiometabolic Conditions and Treatment Options

(S26) High Risk, High Reward: Evaluating GLP1-RA and SGLT2i Therapies, Where the Evidence Is Emerging

Saturday, August 8, 2026
4:00 PM - 4:45 PM ET
CE: .75 CE
Pharmacology Hours: .50 CE
The clinical utility of GLP1-RA, GIP/GLP1-RA, and SGLT2i agents have blossomed, with evidence demonstrating favorable outcomes for both glycemic outcomes and cardiorenal risk reduction. The prevalence of co-morbid cardiorenal conditions in patients with T2D have led to these agents utilized as first-line agents for T2d. GLP1-RA, GIP/GLP1-RA and SGLT2is may require unique considerations prior to prescribing. DCESs must take into account the risks and benefits of these agents in high-risk patient populations. This presentation will review GLP1-RA, GIP/GLP1-RA and SGLT2i classes of medications, with a focus on selection and use in high-risk patient populations.

Learning Objectives:

At the completion of this activity, participants should be able to:
  • Define high-risk populations that require considerations prior to utilizing GLP1-RA, GIP/GLP1-RA, and SGLT2i agents for the treatment of diabetes mellitus.
  • Review the current evidence for using GLP1-RA, GIP/GLP1-RA, and SGLT2i agents in high-risk populations.
  • Formulate a risk-benefit analysis for use of GLP1-RA, GIP/GLP1-RA, and SGLT2i agents in high-risk populations to develop a treatment plan.
Disclosure(s):
Karolyn S. Duprey, PharmD: No financial relationships to disclose
Kristina Naseman, PharmD, MPH, BCACP, BC-ADM, CDCES: No financial relationships to disclose